First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion. The Food and Drug Administration (FDA) has approved Simponi Aria® (golimumab; ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

Johnson & Johnson’s biotech arm, Janssen Biotech, received an expanded indication for its anti-TNF (tumor necrosis factor) infusion therapy, Simponi Aria (golimumab), for patients with ...

Please provide your email address to receive an email when new articles are posted on . Janssen announced it has received FDA approvals for Simponi Aria for the treatment of adults with psoriatic ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...

HORSHAM, Pa. — The Food and Drug Administration this week approved expanded labeling for Janssen Biotech’s rheumatoid arthritis treatment Simponi Aria (golimumab for infusion). The revised label now ...

Johnson & Johnson 's JNJ subsidiary, Janssen Biotech, Inc. announced that it has submitted two Supplemental Biologics License Applications (sBLAs) in the U.S., seeking approval of Simponi Aria for the ...

HORSHAM, Pa., April 24, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...